The Warburg effect not only supports cancer cell proliferation but also contributes to a tumor microenvironment that fosters drug resistance, suggesting that targeting these metabolic pathways may enhance treatment outcomes for patients with estrogen receptor-positive breast cancer [14,17,18]. Here, ESR1 is linked to breast carcinoma.